baber/WOPTO huggingface dataset:
Patent NZ-585176-A (NZ)
Title: Estimating link quality using transmitted reference symbols and adjustment parameters
Inventor: HAMMARWALL DAVID
IPC: H04L1/00
Filed: 2008-06-26
Abstract: Disclosed is an apparatus in a sending node (400) for enabling accurate estimation of the quality of a wireless link to a receiving node. The apparatus contains a sending unit (400a) adapted to send signals to the receiving node (402) over the wireless link. The apparatus also contains a report receiver (400b) to receive at least one link state report from the receiving node (402). The link state reports are based on measurements on reference symbols transmitted by the sending node (400). A link state estimator (400c) is also provided to estimate a current state of the wireless link. A determining unit (400d) is adapted to determine a measurement adjusting parameter for adjusting the measurements on reference symbols if at least one received link state report is deemed inaccurate in relation to the estimated link state. This is determined based on a deviation between the received link state report(s) and the estimated current state of the wireless link. The determining unit (400d) is further configured to send the determined measurement adjusting parameter to the receiving node (402), which enables the receiving node (402) to determine a link quality estimation and/or parameter recommendation based on said signal measurements adjusted by the received measurement adjusting parameter. The report receiver (400b) is further adapted to receive a link state report from the receiving node (402) containing the determined link quality estimation and/or link parameter recommendation which is/are based on the adjusted signal measurements.
Patent NZ-589795-A (NZ)
Title: Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
Inventor: VOLLMERS HEINZ PETER
IPC: G01N33/574
Filed: 2009-06-15
Abstract: Provided is the use of an antibody or functional fragment thereof that binds to NONO/nmt55 protein in the manufacture of a medicament for treating or preventing metastasis of a neoplasia, tumor or cancer in a subject in need of treatment.
Patent NZ-598177-A (NZ)
Title: Fibrous materials and compositions
Inventor: MEDOFF MARSHALL
IPC: B29C48/07
Filed: 2007-06-12
Abstract: ABSTRACT - 598177 The disclosure relates to a method of making a fuel, the method comprising: shearing a cellulosic or lignocellulosic fiber source to provide a first fibrous material; passing the first fibrous material through a first screen having an average opening size of about 1.59 mm or less (1/16 inch, 0.0625 inch) to provide a second fibrous material, the second fibrous material having a BET surface area greater than 0.1 m2/g and a porosity greater than 20 percent and an average length to diameter ratio greater than 5/1; hydrolyzing the second fibrous material to provide a hydrolyzed material; and combining the hydrolyzed material with a bacterium and/or enzyme, the bacterium and/or enzyme utilizing the second fibrous material to produce a fuel, wherein the microorganism hydrolyzes the second fibrous material to produce a fuel comprising hydrogen, an alcohol, an organic acid and/or a hydrocarbon, and wherein the second fibrous material may be sterilized by exposing it to a radiation source prior to combining with the microorganism, and wherein after combining the fibrous material with the bacterium and/or enzyme, a fibrous material composition is produced and this composition is encapsulated in a substantially gas impermeable material followed by removing the entrapped gas from the encapsulated composition to densify the composition..
Patent NZ-600498-A (NZ)
Title: Methods for the treatment and prevention of age-related retinal dysfunction
Inventor: MAEDA TADAO
IPC: A61K31/07
Filed: 2009-02-10
Abstract: 600498 Disclosed is the use of a synthetic retinal derivative for the preparation of a medicament for the treatment or prevention of an impairment in rod-mediated dark adaptation after light exposure, an impairment in night vision, or an impairment in contrast sensitivity in a subject, wherein said medicament is for administration to said subject intermittently with a period between doses of less than once a month over a period of at least three months, wherein said synthetic retinal derivative is a 9-cis-retinyl ester of formula (l) or an 11-cis-retinyl ester of formula (II), wherein A in each formula is CH2OR and R forms said retinyl ester, and the ester substituent of said synthetic retinal derivative comprises a carboxylate radical of a C1-C10 monocarboxylic acid or a C2-C22 polycarboxylic acid.
Patent NZ-617148-A (NZ)
Title: Syngas cooler system and method of operation
Inventor: VANHECKE NICOLAS
IPC: C10J3/72
Filed: 2012-04-04
Abstract: A process and system for cooling syngas provides effective syngas cooling and results in reduced levels of fouling in syngas cooling equipment is disclosed. A process for cooling syngas includes blending syngas with cooled recycled syngas in an amount effective for providing a blended syngas with a temperature at an inlet of a syngas cooler of about 600°F to about 1400°F. The blended syngas changes direction of flow at least once prior to the inlet of the syngas cooler. As shown in the figure, the gas mixing system includes a gasification chamber (100). A syngas recycle inlet (300) enters a distal end or exit section of the gasification chamber (200). In this aspect, the syngas recycle inlet enters the distal end of the gasification chamber tangentially at an outer circumference. Hot syngas leaving the gasifier contacts recycled cooled syngas through the syngas recycle inlet after the hot syngas leaves the gasifier and before the blended syngas enters a syngas cooler (not shown) through a gasification outlet (400). The gasification outlet may be a conduit or pipe. In this aspect, “recycled cooled syngas” refers to a syngas that has been cooled in a syngas cooler to a temperature of about 350°F to about 450°F.
Patent NZ-618786-A (NZ)
Title: Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
Inventor: TURECEK PETER
IPC: A61P7/00
Filed: 2012-07-18
Abstract: The disclosure relates to a method of enhancing blood coagulation in a subject, comprising orally administering to the subject a procoagulant amount of a non-anticoagulant sulphated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer comprising chitosan and bromelain in a manner sufficient to enhance blood coagulation in the subject. The NASP may be a naturally occurring NASP selected from the group consisting of N-acetyl-heparin (NAH), N-acetyl-de-O-sulfated-heparin (NA-de-o-SH), de-N-sulfated-heparin (De-NSH), de-N-sulfated-acetylated-he-parin (De-NSAH), periodate-oxidized heparin (POH), chemically sulfated laminarin (CSL), chemically sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), dextran sulfate (DXS), heparin-derived oligosaccharides (HDO), pentosan polysulfate (PPS) or fucoidans. The NASP may also be a synthetic NASP selected from the group consisting of sulfated oligomers, sulfated pentoses, sulfated hexoses or sulfated cyclodextrins. The gastrointestinal epithelial barrier permeation enhancer may be a tight junction modulator selected from the group consisting of proteases, bile acids, polysaccharides, fatty acids and salts thereof. The disclosure also relates to a composition comprising the NASP and gastrointestinal epithelial barrier permeation enhancer.
Patent NZ-621521-A (NZ)
Title: 1-oxo-isoquinolines and uses thereof
Inventor: REN PINGDA
IPC: C07D487/04
Filed: 2012-07-18
Abstract: Disclosed are PI3 kinase inhibitor compounds of formula (II) wherein the substituents are as defined in the specification. Also disclosed are pharmaceutical compositions comprising compounds of formula (I)I suitable for treating diseases and conditions associated with PI3 kinase activity such as cancer, bone disorder, an inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease, thrombosis, cardiac disease or an auto-immune disease. An example of a compound of formula (II) is: (S)-2-amino-4-((1-(5-(2-methylpyrimidin-5-yl)-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
Patent NZ-622662-A (NZ)
Title: Inhaler
Inventor: ELGAARD SVEND ERIK
IPC: G06M1/20
Filed: 2012-09-12
Abstract: An inhaler (100) for delivery of a medicament by inhalation is disclosed. The inhaler comprises a dispensing mechanism visible through a magnified window (200) , the dispensing mechanism being configured to dispense a dose of medicament on actuation. The inhaler further comprises a dose counting mechanism comprising a counter and a translating member. The translating member comprises a pawl. The counter comprises a first count wheel, a second count wheel and an intermediate wheel engaged with the second count wheel and in selective engagement with the first count wheel. When the inhaler is fired to dispense a dose of medicament, the dispensing mechanism moves the translating member in a substantially linear direction. The pawl thus rotates the first count wheel, and as the first count wheel rotates, the intermediate wheel is selectively engaged thereby selectively rotating the second count wheel to count the doses of the inhaler.
Patent NZ-628874-A (NZ)
Title: Parasiticidal compositions comprising multiple active agents, methods and uses thereof
Inventor: DAS-NANDY ARIMA
IPC: A61P33/00
Filed: 2011-04-01
Abstract: This disclosure relates to compositions for combating ectoparasites and endoparasites in animals, comprising at least one 1-arylpyrazole of formula (I), at least one macrocyclic lactone, at least one insect growth regulator, and at least one anthelmintic compound in combination with a pharmaceutically acceptable carrier. The compositions generally comprises four active agents: two contact-acting active agents and two systemically-acting-active agents. This disclosure also provides for an improved method for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the disclosure to the animal in need thereof.
Patent NZ-701807-A (NZ)
Title: Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Inventor: ANDERBERG JOSEPH
IPC: G01N33/53
Filed: 2011-02-26
Abstract: Disclosed is a method for evaluating renal status in a subject ex vivo, comprising: performing one or more assays configured to detect one or more kidney injury markers in a body fluid sample obtained previously from the subject, wherein at least one of said kidney injury markers is WAP four-disulfide core domain protein 2; determining on the body fluid sample one or more assay results(s); and correlating the assay results to the renal status of the subject, said correlating comprising comparing a measured concentration of WAP four-disulfide core domain protein 2 to a threshold concentration of WAP four-disulfide core domain protein 2 and assigning a likelihood of an event occurring or assigning a likelihood of an event not occurring when the measured concentration varies from the threshold.
Patent NZ-705371-A (NZ)
Title: Gypsum composition, gypsum slurry, gypsum hardened body, gypsum-based construction material, gypsum board, and method for producing gypsum-based construction material
Inventor: ATAKA YUJI
IPC: C04B28/14
Filed: 2013-05-21
Abstract: [Problem] The objective of the present invention is to provide: a gypsum composition that can obtain a high-strength gypsum hardened body without greatly increasing the amount of water added when creating a gypsum slurry; a gypsum slurry; a gypsum hardened body; a gypsum-based construction material; a gypsum board; and a method for producing a gypsum-based construction material. [Solution] Provided are: a gypsum composition containing calcined gypsum and a urea phosphate esterified starch; a gypsum slurry; a gypsum hardened body; a gypsum-based construction material; a gypsum board; and a method for producing a gypsum-based construction material.
Patent NZ-707035-A (NZ)
Title: Gene signatures of inflammatory disorders that relate to the liver
Inventor: PICHAUD MATTHIEU
IPC: C12Q1/68
Filed: 2013-10-17
Abstract: This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn’s and Ulcerative Colitis).These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.
Patent NZ-717213-A (NZ)
Title: Anti-pd-l1 antibodies and their use to enhance t-cell function
Inventor: CHEUNG JEANNE
IPC: C07K16/28
Filed: 2009-12-08
Abstract: Discloses isolated host cells comprising anti programmed death ligand 1 (PD-L1) antibodies or nucleotides encoding anti-PD-L1 antibodies. The anti PD-L1 antibody heavy chain comprises an HVR-H1, HVR-H2 and HVR-H3 with the sequences of GFTFSDSWIH (SEQ ID NO:15), AWISPYGGSTYYADSVKG (SEQ ID NO:16) and RHWPGGFDY (SEQ ID NO:3), respectively. The light chain comprises LVR-L1, LVR-L2 and LVR-L3 with the sequences of RASQDVSTAVA (SEQ ID NO:17), SASFLYS (SEQ ID NO:18) and QQYLYHPAT (SEQ ID NO:19), respectively. Further discloses wherein the heavy chain comprises the sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGG STYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSA (SEQ ID NO:20), and the light chain comprises the sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYH PATFGQGTKVEIKR (SEQ ID NO:21).
Patent NZ-721025-A (NZ)
Title: Delivery of respiratory therapy
Inventor: BRACKENREG SCOTT DOUGLAS
IPC: A61M16/06
Filed: 2007-07-27
Abstract: A patient interface for delivery of a supply of pressurized air or breathable gas to the nares of a person. The patient interface includes a support (623) and a sealing arrangement including a porous sealing portion (622) having a viscoelastic foam interface provided to the support. The viscoelastic foam interface includes a single orifice and has a surface that, in use, is adapted to cradle the person’s external nares and to form a seal in the vicinity of the base of the patient’s nose.
Patent NZ-725089-A (NZ)
Title: Corner assembly for a clothes line frame
Inventor: HUIJI HUI
IPC: F16B7/18
Filed: 2016-10-10
Abstract: Prior art U-shaped cloths frames are generally made from continuous tubing with bends to from corners, this makes for a larger main element which adds to transport costs. Herein is provided a corner assembly for a clothes line frame formed from frame members telescopically extending to engage into tabs of a corner piece. The corner piece provides a contiguous surface which is aesthetically pleasing and conceals metal fasteners which provide strength for the joins. The frame can be shipped as components and readily assembled on site.
Patent NZ-734491-A (NZ)
Title: Method to solubilize curcuminoids in water
Inventor: NAGABHUSHANAM KALYANAM
IPC: A61K47/32
Filed: 2016-02-29
Abstract: A method of solubilizing curcuminoids is disclosed wherein the method uses polyvinyl pyrrolidone and sodium bis (2-ethylhexyl) sulfosuccinate and the aqueous solubility of curcumin/curcuminoid mixtures is enhanced to more than 10%- 15% w/v in water. The present invention also pertains to a curcuminoids composition characterised by not less than 10% w/v, more specifically between 10%- 15% w/v aqueous solubility of curcuminoids in water.
Patent NZ-734496-A (NZ)
Title: Device for holding bait, in particular bait for rodents
Inventor: BITTLINGER WOLFGANG
IPC: A01M25/00
Filed: 2015-02-18
Abstract: The present invention counteracts the problem of contamination of water with substances such as toxins and/or active ingredients that are contained in the corresponding bait. It does so by providing an apparatus (1) for holding bait (2), in particular a bait for rodents, comprising: a housing part (3) that can be inserted into a manhole, in particular a sewer manhole or a cable duct manhole, at least one bait platform (8) arranged in the housing part (3), delimiting at least one passage opening (9) on the bait platform side, through which a rodent can gain access to bait (2) arranged in the housing part (3), wherein when water flows into and/or rises in the housing part (3), a counter-pressure develops in the housing part (3), opposing the inflowing and/or rising water and/or counteracting the inflow and/or rise of water, due to the given volume and the imperviousness of the housing part (3).
Patent NZ-737820-A (NZ)
Title: Mannose derivatives for treating bacterial infections
Inventor: GALLANT MICHEL
IPC: C07D405/14
Filed: 2016-06-13
Abstract: The compounds represented by Formula (I) or pharmaceutically acceptable salts thereof: with U, W, X, Y, Z, p and ring A as defined in claim 1. Those compounds are useful for the treatment or prevention of bacteria infections. The variables of Formula (I) are as described herein. Pharmaceutically acceptable compositions comprise the compounds of Formula (I) or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers, adjuvants, or vehicles. Methods of treating bacteria infections employ such compounds or pharmaceutically acceptable salts thereof.
Patent NZ-738589-A (NZ)
Title: Device for locking down scaffold boards
Inventor: MAHER JUSTIN
IPC: E04G7/28
Filed: 2016-06-30
Abstract: A device (1) for locking down a board (27) of a platform (28) supported on transoms (30) connected between standards (3, 4) of a scaffold. The device includes a riser (5) adapted to be positioned lengthwise of one of the standards, a keeper (6) positioned transversely of the riser to hold the board in place, and a coupling (7) to engage a fitting (8,12) on the standard to lock the device in position. The riser includes a base (22) with an aperture (18) that provides access to a void between upright parts of the riser to accommodate a wedge lock (15) used to connect the platform to the scaffold. The invention provides an alternative means for securing scaffold boards whereby the coupling is laterally shielded from damage and accidental release.
Patent NZ-747187-A (NZ)
Title: Headgear assembly for a respiratory mask assembly
Inventor: GUNEY MEMDUH
IPC: A62B18/08
Filed: 2003-09-05
Abstract: A respiratory mask assembly to deliver breathable gas to a patient, comprising: a nasal mask comprising: a mask frame having a forehead support; a cushion removably connected to the mask frame; and a headgear assembly to stabilize and position a respiratory mask assembly on a patient’s head to maintain the respiratory mask assembly in a desired adjusted position on a patient’s face during use, the headgear assembly comprising: a pair of upper side strap portions, each of the pair of upper side strap portions configured to extend across a corresponding lateral side of the patient’s head and superior to the patient’s corresponding ear and eye in use; a pair of lower side strap portions, each of the pair of lower side strap portions configured to extend across a corresponding lateral side of the patient’s head and inferior to the patient’s corresponding ear in use; an upper strap portion connecting the pair of upper side strap portions and configured to prevent movement of the headgear assembly in an inferior direction on the patient’s head in use; a rear lower strap portion connecting the pair of lower side strap portions; and a rear cross-bar strap portion positioned inferior to the upper strap portion and superior to the rear lower strap portion in use; wherein the upper strap portion and the rear cross-bar strap portion are spaced at a first distance, wherein the rear lower strap portion and the rear cross-bar strap portion are spaced at a second distance, and wherein the first distance is greater than the second distance such that the headgear assembly is configured to accommodate a larger portion of the patient’s head in use between the upper strap portion and the rear cross-bar strap portion than between the rear lower strap portion and the rear cross-bar strap portion.
Patent NZ-759986-A (NZ)
Title: Lifting anchor
Inventor: ARNO GURTLER
IPC: B28B23/00
Filed: 2019-12-09
Abstract: An anchor 1 is embedded in a concrete element to provide for the lifting of the element. An anchor 1 typically includes a head 3 at one end having a lifting eye 5 for releasable engagement with a lifting shackle assembly, and a body 11 extending in a longitudinal direction from the head 3 for embedding within the concrete element. During casting of a concrete element, concrete slurry can seep around the head 3 of the anchor and into the lifting eye 5 making it difficult for a ring clutch of a lifting assembly to access and lift the concrete element. The anchor 1 of the present invention has a head 3 which includes a centrally located main portion 17 in which the lifting eye 5 is formed, and a pair of wing portions 19 provided at opposite ends of the main portion 17, wherein the head 3 is of non-uniform thickness with the thickness of the wing portions 19 being less than the thickness of the main portion 17 such that a ledge 21 is provided between the main portion 17 and wing portions 19. The ledge 21 advantageously minimises the potential for concrete slurry during casting to seep into the lifting eye 5 from between side edges of the anchor head 3 and a removable void former in abutment with opposing faces of the anchor head 3.
Patent NZ-772916-A (NZ)
Title: Patient interface
Inventor: DAVIDSON AARON SAMUEL
IPC: A61M16/04
Filed: 2019-08-20
Abstract: A patient interface may include a plenum chamber pressurisable to a therapeutic pressure, a seal-forming structure constructed and arranged to form a seal with a region of the patient’s face surrounding an entrance to the patient’s airways, a positioning and stabilising structure to provide a force to hold the seal-forming structure in a therapeutically effective position on the patient’s head, and a vent structure to allow a continuous flow of gases exhaled by the patient from an interior of the plenum chamber to ambient, wherein the patient interface is configured to leave the patient’s mouth uncovered during therapy, wherein the seal-forming structure comprises two lateral support regions, each located at a lateralmost side of the seal-forming structure, and a medial region positioned between the lateral support regions, the hole passing through the medial region, wherein the lateral support regions are thicker than the medial region and wherein the seal-forming structure further comprises two mid-lateral regions, each of the mid-lateral regions being positioned laterally outward from and adjacent to the medial region and medially inward from and adjacent to a corresponding one of the lateral support regions, the mid-lateral regions being thicker than the medial region and thinner than the lateral support regions, and the mid-lateral regions being configured to contact the patient’s alae in use, and wherein the seal-forming structure further comprises two corner regions configured to engage the patient’s face at the subalare region, the corner regions being located where the medial region, the mid-lateral regions, and the lateral support regions converge.